Our leadership

We are a passionate team driven by our shared mission of making a significant positive impact on the treatment of childhood cancers. We are building an international consortium made up of drug discovery and development experts, clinical specialists, funders, impact investors and others to advance innovative science into effective and well tolerated therapies.

Executive leadership

Our executive leaders head up a joint management group with strategic oversight and manages partnership, investment and operational activities within the consortium.

The group is made up of members from the founding partners, Cancer Research Horizons and LifeArc.

David Jenkinson

Head of Childhood Cancer Translational Challenge

LifeArc

Tony Hickson

Chief Business Officer

Cancer Research Horizons

Joint steering committee

The joint steering committee approves the sourcing strategy for potential projects, reviews proposed project applications, approves the inclusion of proposed projects into the consortium, oversees the progress of projects, the consortium’s budget and the consortium’s intellectual property, among other responsibilities. The group is made up of members from the founding partners, Cancer Research Horizons and LifeArc.

David Jenkinson

Head of Childhood Cancer Translational Challenge

LifeArc

Hamish Ryder

CEO, Therapeutic Innovation

Cancer Research Horizons

Heather McKinnon

Senior Director, Translational Science

LifeArc

Iain Foulkes

Chief Executive Officer | Executive Director of Research and Innovation

Cancer Research Horizons | Cancer Research UK

Tony Hickson

Chief Business Officer

Cancer Research Horizons

Wendy Jacquemet-Ross

Head of Partnerships, Childhood Cancer

LifeArc

Scientific Advisory Board

Our scientific advisory board provides independent scientific review for new and active consortium projects and portfolio review as well as advises on areas of overall strategy for the consortium. The scientific advisory board is made up of leaders representing a broad range of scientific expertise, including but not limited to, childhood cancer biology, therapeutic discovery, clinical development and unmet need, and the regulatory and commercial landscape.

Additional members to be announced.